NMD Pharma treats first patient with the firm's most promising drug candidate
NMD Pharma company information, funding & investors | Dealroom.co
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
Erhverv Aarhus - 照片| Facebook
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
Roel Bulthuis - Director at NMD Pharma | The Org
NMD Pharma
NMD Pharma raises $47M in series A investment round from INKEF and existing investors, to advance treatments of neuromuscular disorders | Nordic 9
Company Presentation
Klaus Wilhardt - Corporate identity, Design, Logo/navnetræk og designguides
NMD Pharma raises €38M (~USD 47 Million) SERIES A Financing to Advance Treatments of Neuromuscular Disorders
NMD Pharma A/S | LinkedIn
NMD Pharma — NMD Pharma
NMD Pharma
NMD Pharma, finalist i Life Sciences kategorien - EY Danmark
NMD Pharma A/S | LinkedIn
Neuromuscular Drug Development Summit (NMD) - Pharma Journalist
NMD Pharma, finalist i Life Sciences kategorien - EY Danmark
NMD Pharma - PIR International
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis | MENAFN.COM
NMD Pharma | The Org
Denmark in New York on Twitter: "#DKBIO17 is "a great opportunity for us to broaden our scope and look for investors.” - Thomas H. Pedersen, CEO, NMD Pharma… https://t.co/AUeO5JqgX6"
Investors — NMD Pharma
Detailed Description | NMD-GPS
